ID   HeLaSF
AC   CVCL_1278
SY   HELASF; HeLa Serum Free
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-2.3
DR   Cell_Model_Passport; SIDM01209
DR   Cosmic; 687509
DR   GEO; GSM1669876
DR   PharmacoDB; HeLaSF_537_2019
DR   Wikidata; Q54882739
RX   PubMed=20164919;
CC   Group: Serum/protein free medium cell line.
CC   Population: African American.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CCL-2.3; true.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): ATCC=CCL-2.3
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 22
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//